Halozyme Therapeutics Inc (NAS:HALO)
$ 48.13 0.1 (0.21%) Market Cap: 6.12 Bil Enterprise Value: 6.95 Bil PE Ratio: 15.94 PB Ratio: 13.52 GF Score: 87/100

Halozyme Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 11:45PM GMT
Release Date Price: $55.7 (+1.20%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good afternoon, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we are delighted to be continuing the conference with Halozyme. We're going to stay in this room for Q&A after the presentation. So there's 2 ways to ask a question. (Operator Instructions)

So with that out of the way, let me turn it over to Halozyme's CEO, Dr. Helen Torley.

Helen I. Torley
Halozyme Therapeutics, Inc. - President, CEO & Director

Thank you, Jess. 2022 was a transformative year for Halozyme. We project we'll have grown our total revenues by more than 50% to $655 million and growing our royalty revenues by more than 70% to more than $350 million. And we also strengthened our leadership in drug delivery with the addition of our auto-injector platform. I'm pleased to share with you today how this broadened portfolio is resulting in long-term durable growth in both revenue and EBITDA.

In the course of the presentation, I will be making forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot